Syndax Pharmaceuticals Inc (SNDX) research
Syndax Pharmaceuticals Inc- Sector
- Biotechnology
- Last price
- $17.60
- As of
Syndax Pharmaceuticals Inc (SNDX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
As of . Source: SEC EDGAR filings for SNDX. Method and limitations.
Share the SNDX intelligence card
See the full SNDX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SNDX on one page. Preview it with sample data, then open it live with a free account.
Preview the SNDX dossierActive signals for SNDX
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +929% to SNDX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 66% of SNDX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +448% to SNDX (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 22.4%, EPS $-0.55 vs $-0.4493 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 59% of SNDX (2026Q1)
FREE, NO ACCOUNT
Every signal on SNDX, as it fires
You are seeing 5 of 9 signals recorded on SNDX since 2026-06-05.
The five above landed across 3 days. The other 4 were recorded on 1 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SNDX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 87164F105 · 2026Q2 | $44.9M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 87164F105 · 2026Q2 | $34.5M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 87164F105 · 2026Q2 | $27.1M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 87164F105 · 2026Q2 | $7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 87164F105 · 2026Q2 | $5.6M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SNDX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
SNDX against its peers
SNDX's operating margin of -158.4% ranks in the 46th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | SNDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 172M USD | 118M USD | 58 | 12 |
| Operating margin | -158.4% | -85.3% | 46 | 13 |
| Net margin | -165.6% | -85.4% | 46 | 13 |
| Return on equity | -441.6% | -46.3% | 8 | 17 |
Peers (20): IMCR, NTLA, RAPP, GHRS, TSHA, ABSI, FBRX, STOK, NBTX, ANAB, AVBP, MAZE, TYRA, INBX, RARE, VIR, NVAX, ZBIO, DRTS, ORIC. Left out: KLRA (no annual filing), COAG (no annual filing), KALV (no annual filing), AAPG (period gap), KARD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (SNDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SNDX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SNDXand get the insider, 13F, options, and confluence read in one view.